Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-19
2007-06-19
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
09887832
ABSTRACT:
A method for treatment of neurodegenerative disease conditions stemming from multiple sclerosis, aging, autoimmune diseases and fibromyalgia. A compound effective to increase neuronal metabolism of histamine to a histamine H2agonist is administered in an amount sufficient to stimulate production of cyclic AMP at a level which is sufficient to maintain myelin against undergoing self-degeneration. The compound is selected from the group consisting of histamine M-methyltransferase, monoamineoxidase-A, monoamineoxidase-A agonists and histamine H3antagonists. The histamine M-methyltransferase may be administered to increase neuronal metabolism of histamine to tele-methylhistamine, whereas the monoamineoxidase-A or monoamineoxidase-A agonist may be administered so as to increase neuronal metabolism of telemethylhistamine to an H2agonist. Separately or in conjunction with the others, the histamine H3antagonist may be administered so as to inhibit metabolism of the telemethylhistamine to an H3agonist, thereby increasing metabolism of the telemethylhistamine to an H2agonist. The increased histamine H2agonist levels reduce demyelination and the symptoms that are associated with these conditions.
REFERENCES:
patent: 4409243 (1983-10-01), Lieb
patent: 4521405 (1985-06-01), McMichael
patent: 4705685 (1987-11-01), McMichael
patent: 4769322 (1988-09-01), Henry et al.
patent: 7672577 (1992-01-01), Epstein et al.
patent: 5264459 (1993-11-01), Chelmicka-Schorr
patent: 5672622 (1997-09-01), Hedgepeth et al.
patent: 5780026 (1998-07-01), Yoshii et al.
patent: 5821259 (1998-10-01), Theoharides
patent: 5889033 (1999-03-01), Kaminski
patent: 6025395 (2000-02-01), Breitner et al.
patent: 6071889 (2000-06-01), Weiss et al.
patent: 6117912 (2000-09-01), DiSanto
patent: 6242492 (2001-06-01), Bergeron, Jr.
patent: 903866 (1962-08-01), None
patent: 1640653 (1991-04-01), None
patent: WO 9100730 (1991-01-01), None
patent: WO-96/11009 (1995-04-01), None
patent: WO95289926 (1995-11-01), None
patent: WO 9802165 (1998-01-01), None
Greenberg et al, b-adrenergic receptors in aging rat brain, 1978, Recent Adv. Pharmacol. Adrenoreceptors, Proc. Satell. Symp. Int. Congr. Pharmacol., 7th, 241-50.
Management of Multiple Sclerosis—Jonez, M.D., (May 1952 pp. 415-422).
Transdermal Histamine in Multiple Sclerosis—Gilson, G., (Dec. 1999, pp. 424-428).
Hathaway Todd N.
Pryor Alton
LandOfFree
Method for treatment of neurodegenerative diseases and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of neurodegenerative diseases and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of neurodegenerative diseases and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3860330